{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-142331","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.930824+00:00","generated_at":"2026-06-26T00:01:06.846257+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tyra Biosciences Q1 net loss $14.8M; cash $292.5M; IND filings on track for 2022","bullets":["Net loss of $14.8M in Q1 2022 vs $4.2M in Q1 2021, driven by higher R&D and G&A expenses.","R&D expense $9.6M (up from $3.5M); G&A expense $5.2M (up from $0.7M).","Cash and equivalents $292.5M as of March 31, 2022, supporting pipeline into clinical stage.","IND for TYRA-300 (FGFR3 inhibitor) expected mid-2022; TYRA-200 (FGFR2) IND in H2 2022.","Pipeline includes programs in achondroplasia, RET, and FGFR4-driven cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-142331","json":"https://secwatch.observer/filing/0001193125-22-142331.json","markdown":"https://secwatch.observer/filing/0001193125-22-142331.md","text":"https://secwatch.observer/filing/0001193125-22-142331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312522142331/0001193125-22-142331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312522142331/d350831d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:01:06.846257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}